Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 297 (5585): 1330-1333

Copyright © 2002 by the American Association for the Advancement of Science

Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether

Hyun-Soo Cho, Daniel J. Leahy*

We have determined the 2.6 angstrom crystal structure of the entire extracellular region of human HER3 (ErbB3), a member of the epidermal growth factor receptor (EGFR) family. The structure consists of four domains with structural homology to domains found in the type I insulin-like growth factor receptor. The HER3 structure reveals a contact between domains II and IV that constrains the relative orientations of ligand-binding domains and provides a structural basis for understanding both multiple-affinity forms of EGFRs and conformational changes induced in the receptor by ligand binding during signaling. These results also suggest new therapeutic approaches to modulating the behavior of members of the EGFR family.

Department of Biophysics and Biophysical Chemistry, Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.
*   To whom correspondence should be addressed. E-mail: leahy{at}groucho.med.jhmi.edu



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Effective Targeting of the Epidermal Growth Factor Receptor (EGFR) for Treating Oral Cancer: A Promising Approach.
F. A. P. RIBEIRO, J. NOGUTI, C. T. F. OSHIMA, and D. A. RIBEIRO (2014)
Anticancer Res 34, 1547-1552
   Abstract »    Full Text »    PDF »
The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases.
M. A. Lemmon, J. Schlessinger, and K. M. Ferguson (2014)
Cold Spring Harb Perspect Biol 6, a020768
   Abstract »    Full Text »    PDF »
Molecular Pathways: HER3 Targeted Therapy.
K. Gala and S. Chandarlapaty (2014)
Clin. Cancer Res. 20, 1410-1416
   Abstract »    Full Text »    PDF »
Role of erbB3 receptors in cancer therapeutic resistance.
Y. Lee, J. Ma, H. Lyu, J. Huang, A. Kim, and B. Liu (2014)
Acta Biochim Biophys Sin 46, 190-198
   Abstract »    Full Text »    PDF »
Suppression of Heregulin {beta} Signaling by the Single N-Glycan Deletion Mutant of Soluble ErbB3 Protein.
M. Takahashi, Y. Hasegawa, Y. Ikeda, Y. Wada, M. Tajiri, S. Ariki, R. Takamiya, C. Nishitani, M. Araki, Y. Yamaguchi, et al. (2013)
J. Biol. Chem. 288, 32910-32921
   Abstract »    Full Text »    PDF »
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin.
A. P. Garner, C. U. Bialucha, E. R. Sprague, J. T. Garrett, Q. Sheng, S. Li, O. Sineshchekova, P. Saxena, C. R. Sutton, D. Chen, et al. (2013)
Cancer Res. 73, 6024-6035
   Abstract »    Full Text »    PDF »
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation.
C. Mirschberger, C. B. Schiller, M. Schraml, N. Dimoudis, T. Friess, C. A. Gerdes, U. Reiff, V. Lifke, G. Hoelzlwimmer, I. Kolm, et al. (2013)
Cancer Res. 73, 5183-5194
   Abstract »    Full Text »    PDF »
Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family.
A. Arkhipov, Y. Shan, E. T. Kim, R. O. Dror, and D. E. Shaw (2013)
eLife Sci 2, e00708
   Abstract »    Full Text »    PDF »
Mechanisms for Kinase-mediated Dimerization of the Epidermal Growth Factor Receptor.
C. Lu, L.-Z. Mi, T. Schurpf, T. Walz, and T. A. Springer (2012)
J. Biol. Chem. 287, 38244-38253
   Abstract »    Full Text »    PDF »
Dynamically varying interactions between heregulin and ErbB proteins detected by single-molecule analysis in living cells.
M. Hiroshima, Y. Saeki, M. Okada-Hatakeyama, and Y. Sako (2012)
PNAS 109, 13984-13989
   Abstract »    Full Text »    PDF »
Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.
Q. Zhang, E. Park, K. Kani, and R. Landgraf (2012)
PNAS 109, 13237-13242
   Abstract »    Full Text »    PDF »
A single ligand is sufficient to activate EGFR dimers.
P. Liu, T. E. Cleveland IV, S. Bouyain, P. O. Byrne, P. A. Longo, and D. J. Leahy (2012)
PNAS 109, 10861-10866
   Abstract »    Full Text »    PDF »
Reply to P. Bohanes et al.
M. D. Begnami (2012)
J. Clin. Oncol. 30, 466-467
   Full Text »    PDF »
Structural Insights into the Down-regulation of Overexpressed p185her2/neu Protein of Transformed Cells by the Antibody chA21.
H. Zhou, Z. Zha, Y. Liu, H. Zhang, J. Zhu, S. Hu, G. Shen, L. Cheng, L. Niu, M. I. Greene, et al. (2011)
J. Biol. Chem. 286, 31676-31683
   Abstract »    Full Text »    PDF »
Engineered Bivalent Ligands to Bias ErbB Receptor-mediated Signaling and Phenotypes.
S. M. Jay, E. Kurtagic, L. M. Alvarez, S. de Picciotto, E. Sanchez, J. F. Hawkins, R. N. Prince, Y. Guerrero, C. L. Treasure, R. T. Lee, et al. (2011)
J. Biol. Chem. 286, 27729-27740
   Abstract »    Full Text »    PDF »
Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.
Y.-C. Liu, H.-Y. Yen, C.-Y. Chen, C.-H. Chen, P.-F. Cheng, Y.-H. Juan, C.-H. Chen, K.-H. Khoo, C.-J. Yu, P.-C. Yang, et al. (2011)
PNAS 108, 11332-11337
   Abstract »    Full Text »    PDF »
Kinase-mediated quasi-dimers of EGFR.
E. M. Bublil, G. Pines, G. Patel, G. Fruhwirth, T. Ng, and Y. Yarden (2010)
FASEB J 24, 4744-4755
   Abstract »    Full Text »    PDF »
The Extracellular Domain of Fibroblast Growth Factor Receptor 3 Inhibits Ligand-Independent Dimerization.
L. Chen, J. Placone, L. Novicky, and K. Hristova (2010)
Science Signaling 3, ra86
   Abstract »    Full Text »    PDF »
Emerging Strategies for ErbB Ligand-based Targeted Therapy for Cancer.
H. TSUJIOKA, F. YOTSUMOTO, K. SHIROTA, S. HORIUCHI, T. YOSHIZATO, M. KUROKI, and S. MIYAMOTO (2010)
Anticancer Res 30, 3107-3112
   Abstract »    Full Text »    PDF »
Roles for Growth Factors in Cancer Progression.
E. Witsch, M. Sela, and Y. Yarden (2010)
Physiology 25, 85-101
   Abstract »    Full Text »    PDF »
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
N. Jura, Y. Shan, X. Cao, D. E. Shaw, and J. Kuriyan (2009)
PNAS 106, 21608-21613
   Abstract »    Full Text »    PDF »
Oncogenic EGFR Signaling Networks in Glioma.
P. H. Huang, A. M. Xu, and F. M. White (2009)
Science Signaling 2, re6
   Abstract »    Full Text »    PDF »
Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix.
J. Kalinina, S. A. Byron, H. P. Makarenkova, S. K. Olsen, A. V. Eliseenkova, W. J. Larochelle, M. Dhanabal, S. Blais, D. M. Ornitz, L. A. Day, et al. (2009)
Mol. Cell. Biol. 29, 4663-4678
   Abstract »    Full Text »    PDF »
All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.
R.-H. Tao and I. N. Maruyama (2008)
J. Cell Sci. 121, 3207-3217
   Abstract »    Full Text »    PDF »
Mutational Activation of ErbB2 Reveals a New Protein Kinase Autoinhibition Mechanism.
Y.-X. Fan, L. Wong, J. Ding, N. A. Spiridonov, R. C. Johnson, and G. R. Johnson (2008)
J. Biol. Chem. 283, 1588-1596
   Abstract »    Full Text »    PDF »
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib.
T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al. (2008)
Cancer Res. 68, 571-579
   Abstract »    Full Text »    PDF »
Targeting Human Epidermal Growth Factor Receptor 2: It Is Time to Kill Kinase Death Human Epidermal Growth Factor Receptor 3.
J. A. Menendez and R. Lupu (2007)
J. Clin. Oncol. 25, 2496-2498
   Full Text »    PDF »
The Asn418-Linked N-Glycan of ErbB3 Plays a Crucial Role in Preventing Spontaneous Heterodimerization and Tumor Promotion.
S. Yokoe, M. Takahashi, M. Asahi, S. H. Lee, W. Li, D. Osumi, E. Miyoshi, and N. Taniguchi (2007)
Cancer Res. 67, 1935-1942
   Abstract »    Full Text »    PDF »
Targeting HER2 in Prostate Cancer: Where to Next?.
D. B. Solit and N. Rosen (2007)
J. Clin. Oncol. 25, 241-243
   Full Text »    PDF »
Single-molecule analysis of epidermal growth factor binding on the surface of living cells.
Y. Teramura, J. Ichinose, H. Takagi, K. Nishida, T. Yanagida, and Y. Sako (2006)
EMBO J. 25, 4215-4222
   Abstract »    Full Text »    PDF »
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
S. Bouyain, P. A. Longo, S. Li, K. M. Ferguson, and D. J. Leahy (2005)
PNAS 102, 15024-15029
   Abstract »    Full Text »    PDF »
Epidermal Growth Factor Receptor Dimerization and Activation Require Ligand-Induced Conformational Changes in the Dimer Interface.
J. P. Dawson, M. B. Berger, C.-C. Lin, J. Schlessinger, M. A. Lemmon, and K. M. Ferguson (2005)
Mol. Cell. Biol. 25, 7734-7742
   Abstract »    Full Text »    PDF »
Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis.
A. H. A. Clayton, F. Walker, S. G. Orchard, C. Henderson, D. Fuchs, J. Rothacker, E. C. Nice, and A. W. Burgess (2005)
J. Biol. Chem. 280, 30392-30399
   Abstract »    Full Text »    PDF »
The epidermal growth factor receptor family.
L A Bazley and W J Gullick (2005)
Endocr. Relat. Cancer 12, S17-S27
   Abstract »    Full Text »    PDF »
A Structural Model for the Membrane-bound Form of the Juxtamembrane Domain of the Epidermal Growth Factor Receptor.
K. Choowongkomon, C. R. Carlin, and F. D. Sonnichsen (2005)
J. Biol. Chem. 280, 24043-24052
   Abstract »    Full Text »    PDF »
Oligomers of ERBB3 Have Two Distinct Interfaces That Differ in Their Sensitivity to Disruption by Heregulin.
K. Kani, C. M. Warren, C. S. Kaddis, J. A. Loo, and R. Landgraf (2005)
J. Biol. Chem. 280, 8238-8247
   Abstract »    Full Text »    PDF »
Targeting ErbB receptor signaling: A pan-ErbB approach to cancer.
C. D. Britten (2004)
Mol. Cancer Ther. 3, 1335-1342
   Abstract »    Full Text »    PDF »
Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor.
T. G. Johns, T. E. Adams, J. R. Cochran, N. E Hall, P. A. Hoyne, M. J. Olsen, Y.-S. Kim, J. Rothacker, E. C. Nice, F. Walker, et al. (2004)
J. Biol. Chem. 279, 30375-30384
   Abstract »    Full Text »    PDF »
CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor.
F. Walker, S. G. Orchard, R. N. Jorissen, N. E. Hall, H.-H. Zhang, P. A. Hoyne, T. E. Adams, T. G. Johns, C. Ward, T. P. J. Garrett, et al. (2004)
J. Biol. Chem. 279, 22387-22398
   Abstract »    Full Text »    PDF »
Mechanistic Diversity of Cytokine Receptor Signaling Across Cell Membranes.
R. M. Stroud and J. A. Wells (2004)
Sci. STKE 2004, re7
   Abstract »    Full Text »    PDF »
The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function.
D. Mattoon, P. Klein, M. A. Lemmon, I. Lax, and J. Schlessinger (2004)
PNAS 101, 923-928
   Abstract »    Full Text »    PDF »
A structure-based model for ligand binding and dimerization of EGF receptors.
P. Klein, D. Mattoon, M. A. Lemmon, and J. Schlessinger (2004)
PNAS 101, 929-934
   Abstract »    Full Text »    PDF »
Structural Analysis of an Epidermal Growth Factor/Transforming Growth Factor-{alpha} Chimera with Unique ErbB Binding Specificity.
M. Wingens, T. Walma, H. van Ingen, C. Stortelers, J. E. M. van Leeuwen, E. J. J. van Zoelen, and G. W. Vuister (2003)
J. Biol. Chem. 278, 39114-39123
   Abstract »    Full Text »    PDF »
Intrinsic susceptibility to misfolding of a hot-spot for Hirschsprung disease mutations in the ectodomain of RET.
S. Kjaer and C. F. Ibanez (2003)
Hum. Mol. Genet. 12, 2133-2144
   Abstract »    Full Text »    PDF »
Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
C.-h. B. Chen, G. A. Chernis, V. Q. Hoang, and R. Landgraf (2003)
PNAS 100, 9226-9231
   Abstract »    Full Text »    PDF »
SIGNAL TRANSDUCTION: Autoinhibition Control.
J. Schlessinger (2003)
Science 300, 750-752
   Abstract »    Full Text »    PDF »
Selective Formation of ErbB-2/ErbB-3 Heterodimers Depends on the ErbB-3 Affinity of Epidermal Growth Factor-like Ligands.
C. Stortelers, S. P. van der Woning, S. Jacobs-Oomen, M. Wingens, and E. J. J. van Zoelen (2003)
J. Biol. Chem. 278, 12055-12063
   Abstract »    Full Text »    PDF »
Stabilizing the open conformation of the integrin headpiece with a glycan wedge increases affinity for ligand.
B.-H. Luo, T. A. Springer, and J. Takagi (2003)
PNAS 100, 2403-2408
   Abstract »    Full Text »    PDF »
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor.
J. Stamos, M. X. Sliwkowski, and C. Eigenbrot (2002)
J. Biol. Chem. 277, 46265-46272
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882